Navigating the Clinical Research Process for Glioma
NCT05958472 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2023-07-24
Summary
Participation in medical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.
This trial will admit a wide range of data on the clinical trial experience of glioma patients to determine which factors prevail in limiting a patient's ability to join or finish a trial.
It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future glioma patients.
Conditions
Sponsors & Collaborators
-
Power Life Sciences Inc.
lead INDUSTRY
Principal Investigators
-
Michael B Gill · Power Life Sciences Inc.
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-08-31
- Primary Completion
- 2025-08-31
- Completion
- 2026-08-31
Countries
- United States
Study Locations
More Related Trials
-
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
NCT01268566 ·Status: COMPLETED ·Phase: PHASE2
-
Predicting Response Patterns to Treatment in Glioblastoma (GBM) Patients
NCT04219475 ·Status: SUSPENDED
-
CC-5013 in Treating Patients With Recurrent Glioma
NCT00036894 ·Status: COMPLETED ·Phase: PHASE1
-
First in Patient Study for PF-06840003 in Malignant Gliomas
NCT02764151 ·Status: TERMINATED ·Phase: PHASE1
-
Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
NCT03072134 ·Status: COMPLETED ·Phase: PHASE1
-
Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma
NCT00017264 ·Status: COMPLETED ·Phase: PHASE1
-
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
NCT06319027 ·Status: RECRUITING ·Phase: PHASE2
-
Examination of Changes on Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) in Patients Who Receive Gliadel Wafers During Initial Surgery for Glioblastoma Multiforme. Response or Failure to Gliadel Wafers for Subjects With Glioblastoma Multiforme.
NCT00645385 ·Status: WITHDRAWN
-
Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma
NCT00087061 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas
NCT00074646 ·Status: COMPLETED ·Phase: PHASE1
-
Disease Progression and Treatment-induced Alterations in Glioblastoma
NCT02152748 ·Status: UNKNOWN
-
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
NCT02586857 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Cilengitide Imaging Trial in Glioblastoma
NCT01558687 ·Status: TERMINATED ·Phase: PHASE1
-
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
NCT00025675 ·Status: COMPLETED ·Phase: PHASE2
-
Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies
NCT00897663 ·Status: COMPLETED
-
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
NCT00679354 ·Status: COMPLETED ·Phase: PHASE2
-
Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00014170 ·Status: COMPLETED ·Phase: PHASE2
-
Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer
NCT00525590 ·Status: COMPLETED ·Phase: PHASE2
-
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
NCT00093964 ·Status: COMPLETED ·Phase: PHASE2
-
The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients
NCT05063682 ·Status: UNKNOWN ·Phase: PHASE1
-
Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma
NCT00093613 ·Status: COMPLETED ·Phase: PHASE1
-
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
NCT05789394 ·Status: RECRUITING ·Phase: PHASE1
-
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
NCT03770468 ·Status: COMPLETED
-
Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme
NCT00112866 ·Status: TERMINATED ·Phase: PHASE2
-
A Dose-Escalation Study in Participants With Recurrent Malignant Glioma
NCT01682187 ·Status: COMPLETED ·Phase: PHASE1